Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Revelation is a clinical-stage life science company developing therapeutics based on its proprietary Gemini formulation (PHAD), a Toll-like receptor 4 (TLR4) agonist. The company focuses on three primary programs: GEM-AKI (prevention of acute kidney injury), GEM-CKD (treatment of chronic kidney disease), and GEM-PSI (prevention of post-surgical infection). The company has no products approved for commercial sale and has incurred net losses since inception.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15.04) million | $(0.12) million |
| Operating Expenses | $7.98 million | $8.66 million |
| Cash and Cash Equivalents (Year-End) | $6.50 million | $11.99 million |
| Accumulated Deficit | $(40.51) million | $(25.47) million |
| Stockholders' Equity | $4.71 million | $6.65 million |
| Net Cash Used in Operating Activities | $(18.32) million | $(7.29) million |
Note: The company reported no revenue for either period. The 2024 net loss was significantly impacted by non-operating expenses, including a LifeSci Capital LLC judgment expense and clinical trial settlement costs.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased from $0.12 million in 2023 to $15.04 million in 2024. This was primarily driven by a shift in "Other (expense) income, net" from a gain of $8.54 million in 2023 (due to a decrease in warrant liability fair value) to an expense of $7.06 million in 2024.
- Operating Expenses: Total operating expenses decreased slightly by $0.68 million (from $8.66 million to $7.98 million). This was due to a $2.11 million decrease in "Other program expenses" and a $0.31 million decrease in manufacturing expenses, partially offset by a $1.47 million increase in clinical study expenses for the GEM-AKI, GEM-CKD, and GEM-PSI programs.
- Liquidity: Cash and cash equivalents decreased by approximately $5.49 million, reflecting high operating cash burn despite $12.85 million in financing proceeds during 2024.
- Capital Structure: The company raised approximately $12.8 million in 2024 through public offerings and warrant exercises (Class D and Class E inducements). The company also effected a 1-for-30 reverse stock split in January 2024 and a 1-for-16 reverse stock split in January 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, the company had $6.5 million in cash, which is not sufficient to sustain operations for one year following the issuance of the financial statements. The company plans to seek additional funding through equity or debt financings, but there is no guarantee such funding will be available on acceptable terms.
Clinical Development Outlook
- GEM-AKI & GEM-CKD: Phase 1b clinical studies in CKD patients began in January 2025. Data is expected in the first half of 2025. A subsequent Phase 1b study in cardiac surgery patients is planned.
- GEM-PSI: The company is evaluating next steps for development following Phase 1 data announced in June 2024.
Unusual Items
- Legal and Settlement Costs: The 2024 "Other (expense) income, net" included significant expenses related to a LifeSci Capital LLC judgment, reimbursement of legal costs, and clinical trial settlement expenses with A-IR Clinical Research Ltd.
- Warrant Liability: In 2023, the company recognized a non-cash gain of $8.33 million due to the change in fair value of warrant liabilities. In 2024, this resulted in a non-cash gain of only $0.08 million, contributing to the higher net loss.
Risks
- Regulatory Approval: No products are approved; success depends on clinical trial outcomes and FDA/EMA acceptance of data from studies conducted outside the U.S.
- Supply Chain: Reliance on a single supplier (Avanti Polar Lipids, Inc.) for the active pharmaceutical ingredient (PHAD) without a long-term supply agreement.
- Listing Compliance: The company previously received notice of non-compliance with Nasdaq minimum bid price requirements but regained compliance in February 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.5 million cash balance against current burn rates and the timeline for securing additional financing.
- Legal Contingencies: Review the specific details and potential future liabilities associated with the LifeSci Capital LLC judgment and A-IR Clinical Research Ltd. settlement.
- Supply Agreements: Confirm the status of supply agreements with Avanti Polar Lipids, Inc. for PHAD to ensure continuity of clinical trials.
- Warrant Inducements: Assess the dilution impact of the Class D and Class E warrant inducements and the terms of the newly issued Class F and Class G warrants.
- Clinical Data: Monitor the release of Phase 1b data for GEM-AKI and GEM-CKD expected in the first half of 2025.